(secondQuint)A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer.

 1.

 To evaluate the safety and tolerability of oral Selatinib Ditosilate Tablets, and explore the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).

 2.

 To determine the pharmacokinetic profile of single and multi oral Selatinib Ditosilate Tablets .

 3.

 To determine preliminary dose and regimen for phase II study of oral Selatinib Ditosilate Tablets.

 4.

 To assess preliminary antitumor activity .

.

 A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer@highlight

Brief Description: This study is designed to evaluate the safety and tolerability of oral Selatinib Ditosilate Tablets, and explore the maximum tolerated dose (MTD) and dose-limiting toxicity in patients with advanced breast cancer.

